{"entity":{"id":"nct05101096","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors","aka":["ASCENT-J02"],"tldr":"A phase 1/2 trial of Sacituzumab govitecan in triple-negative breast cancer and bladder & urothelial cancer, run by Gilead Sciences, active and no longer recruiting.","summary":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05101096 by Gilead Sciences, with 135 participants enrolled, started 2021-10-20 and due to reach its primary completion in 2027-05. Interventions recorded: Sacituzumab Govitecan-hziy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05101096","url":"https://clinicaltrials.gov/study/NCT05101096"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","urothelial"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["sacituzumab-govitecan"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05101096-int-j-clin-oncol-2024"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05101096","phase":"1/2","setting":"A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)","sponsor":"Gilead Sciences","started":"2021-10-20","startedType":"actual","enrolled":135,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05101096/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}],"paper":[{"id":"paper-nct05101096-int-j-clin-oncol-2024","kind":"paper","name":"Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","route":"/key-papers/paper-nct05101096-int-j-clin-oncol-2024/"}]}}